ReviewWorld journal of urology2004
The role of positron emission tomography in germ cell cancer.
Review in World journal of urology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Positron emission tomography (PET) in the urooncological evaluation of the small pelvis.World journal of urology · 2007Pooled it
- [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].Der Urologe. Ausg. A · 2004Pooled it
- FDG PET Hybrid Imaging.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Nuclear medicine imaging in non-seminomatous germ cell tumors: lessons learned from the past failures.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Lymph Node Dissection in Testicular Cancer: The State of the Art and Future Perspectives.Current oncology reports · 2024Review
- Performance characteristics ofCanadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- [Positron-emission tomography in urooncology].Der Urologe. Ausg. A · 2015Article
- 18F-FDG PET/CT impact on testicular tumours clinical management.European journal of nuclear medicine and molecular imaging · 2014Article
- Article
- Suture Granuloma Showing False-Positive Findings on FDG-PET.Case reports in urology · 2013Article
- In vivo molecular MRI of cell survival and teratoma formation following embryonic stem cell transplantation into the injured murine myocardium.Magnetic resonance in medicine · 2011Article
- Lymphotropic nanoparticle enhanced MRI for the staging of genitourinary tumors.Nature reviews. Urology · 2010Review
- Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report.Cases journal · 2009Article
- [Impact of nuclear medicine imaging techniques for lymph node surgery].Der Urologe. Ausg. A · 2009Review
- Atypical basal ganglia germinoma presenting as cerebral hemiatrophy: diagnosis and follow-up with 11C-methionine positron emission tomography.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2009Article
- [Value of imaging for lymph node metastases from renal cell, bladder, prostate, penile, and testicular cancers].Der Urologe. Ausg. A · 2005Review
- Management of urological malignancies: Has positron emission tomography/computed tomography made a difference?Indian journal of urology : IJU : journal of the Urological Society of IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron emission tomography (PET) is a non-invasive tool for imaging regional metabolic processes, which adds another dimension to current anatomy-derived imaging techniques, i.e. metabolic imaging. To date, 2-(18)fluoro-2-deoxy-D-glucose (FDG) has been the only tracer used for imaging germ cell tumors (GCT), which can be distinguished from normal tissue by their different glucose utilization. However, FDG PET has several limitations: (1) inflammatory and granulomatous tissues also show extensive FDG uptake, (2) lesions <1 cm in size can often not be detected, and (3) mature teratoma is indistinguishable from normal and necrotic tissue. Studies assessing the clinical role of FDG PET in GCT suggest that the technique has a place as a standard tool in evaluating post chemotherapy seminoma residuals. Whether it also improves the assessment of the risks carried by clinical stage I non-seminoma patients and the early prediction of response to salvage chemotherapy is still under investigation, or at least needs to be confirmed by further trials. In relapsing patients with a mismatch between tumor markers and imaging data, FDG PET appears to be useful whenever salvage surgery is considered, although systematic trials are not yet available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.